Posted by Michael Wonder on 25 May 2022
Verrica receives complete response letter from the FDA for its NDA for VP-102
24 May 2022 - Verrica has been advised that pre-approval inspection was conducted at Sterling and is not aware of any reported observations related to the pre-approval inspection of VP-102 operations.
Verrica Pharmaceuticals today announced that the U.S. FDA has issued a complete response letter regarding its new drug application for VP-102 for the treatment of molluscum contagiosum.
